U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubChem Compound

Items: 1 to 20 of 96

1.
Assay-guided treatment sequencing in chronic lymphocytic leukemia (CLL): a cost-effectiveness analysis
Samantha Pollard, Brandon Chan, Alina S. Gerrie, Adam J. N. Raymakers, Dean A. Regier
Sci Rep. 2024; 14: 17294. Published online 2024 Jul 27. doi: 10.1038/s41598-024-68431-6
PMCID:
PMC11283533
AbstractArticlePDF–1.0M
2.
Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials
Matthew S. Davids, Jeff P. Sharman, Paolo Ghia, Jennifer A. Woyach, Toby A. Eyre, Wojciech Jurczak, Tanya Siddiqi, Paulo Miranda, Mina Shahkarami, Anna Butturini, Ugochinyere Emeribe, John C. Byrd
Blood Adv. 2024 Jul 9; 8(13): 3345–3359. Published online 2024 Apr 22. doi: 10.1182/bloodadvances.2023011307
PMCID:
PMC11255369
AbstractArticlePDF–1.7M
3.
Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis
Shuo Yin, Xiaohong Zheng, Weichunbai Zhang, Hanyun Zhao, Rong Zhang, Wenbin Li, Feng Chen
Ann Hematol. 2024; 103(7): 2231–2244. Published online 2023 Oct 16. doi: 10.1007/s00277-023-05486-x
PMCID:
PMC11224099
AbstractArticlePDF–1.2M
4.
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies
Linlin Xu, Mazyar Shadman, Ian W. Flinn, Moshe Y. Levy, Ryan Porter, John M. Burke, Syed F. Zafar, Jennifer L. Cultrera, Jamal Misleh, Edwin C. Kingsley, Habte A. Yimer, Benjamin Freeman, Arvind Chaudhry, Praveen K. Tumula, Mitul D. Gandhi, Rocco Crescenzo, Kunthel By, Aileen Cohen, Dih Yih Chen, Adam Idoine, Sudhir Manda, Jeff P. Sharman, Vanitha Ramakrishnan
Haematologica. 2024 Jul 1; 109(7): 2284–2289. Published online 2024 Jan 25. doi: 10.3324/haematol.2023.283861
PMCID:
PMC11215392
ArticlePDF–5.3M
5.
An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL
Adam S. Kittai, John N. Allan, Dan James, Helen Bridge, Miguel Miranda, Alan S. M. Yong, Fady Fam, Jack Roos, Vikram Shetty, Alan Skarbnik, Matthew S. Davids
Blood Adv. 2024 Jun 11; 8(11): 2861–2869. Published online 2024 Apr 12. doi: 10.1182/bloodadvances.2023012142
PMCID:
PMC11176945
AbstractArticlePDF–934K
6.
Arrhythmogenic Ventricular Remodeling by Next-Generation Bruton’s Tyrosine Kinase Inhibitor Acalabrutinib
Yanan Zhao, Praloy Chakraborty, Julianna Tomassetti, Tasnia Subha, Stéphane Massé, Paaladinesh Thavendiranathan, Filio Billia, Patrick F. H. Lai, Husam Abdel-Qadir, Kumaraswamy Nanthakumar
Int J Mol Sci. 2024 Jun; 25(11): 6207. Published online 2024 Jun 5. doi: 10.3390/ijms25116207
PMCID:
PMC11173147
AbstractArticlePDF–7.5M
7.
Bruton’s tyrosine kinase inhibition limits endotoxic shock by suppressing IL-6 production by marginal zone B cells in mice
Kazuhiko Kawata, Shinya Hatano, Akemi Baba, Keisuke Imabayashi, Yoshihiro Baba
Front Immunol. 2024; 15: 1388947. Published online 2024 Apr 4. doi: 10.3389/fimmu.2024.1388947
PMCID:
PMC11024364
AbstractArticlePDF–2.2M
8.
Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial
Changhee Park, Ho Sup Lee, Ka-Won Kang, Won-Sik Lee, Young Rok Do, Jae-Yong Kwak, Ho-Jin Shin, Sung-Yong Kim, Jun Ho Yi, Sung-Nam Lim, Jeong-Ok Lee, Deok-Hwan Yang, Hun Jang, Byoungsan Choi, Jiwoo Lim, Choong Hyun Sun, Ja Min Byun, Sung-Soo Yoon, Youngil Koh
Nat Commun. 2024; 15: 2776. Published online 2024 Mar 30. doi: 10.1038/s41467-024-47198-4
PMCID:
PMC10981676
AbstractArticlePDF–1.0M
9.
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors
Steven Le Gouill, Monika Długosz-Danecka, Simon Rule, Pier Luigi Zinzani, Andre Goy, Stephen D. Smith, Jeanette K. Doorduijn, Carlos Panizo, Bijal D. Shah, Andrew J. Davies, Richard Eek, Eric Jacobsen, Arnon P. Kater, Tadeusz Robak, Preetesh Jain, Roser Calvo, Lin Tao, Michael Wang
Haematologica. 2024 Jan 1; 109(1): 343–350. Published online 2023 Jul 20. doi: 10.3324/haematol.2022.282469
PMCID:
PMC10772531
ArticlePDF–3.8M
10.
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
John F. Seymour, John C. Byrd, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O’Brien, Jennifer R. Brown, Talha Munir, Anthony Mato, Stephan Stilgenbauer, Naghmana Bajwa, Paulo Miranda, Kara Higgins, Ellie John, Marianne de Borja, Wojciech Jurczak, Jennifer A. Woyach
Blood. 2023 Aug 24; 142(8): 687–699. Published online 2023 Jul 3. doi: 10.1182/blood.2022018818
PMCID:
PMC10644206
AbstractArticle
11.
Acalabrutinib and steroid for autoimmune thrombocytopenia due to relapsed chronic lymphocytic leukemia with severe bone marrow infiltration
Takashi Oyama, Megumi Yasunaga, Masahiro Jona, Masako Nishikawa, Yutaka Yatomi, Akira Honda, Hiroaki Maki, Ken Morita, Yosuke Masamoto, Mineo Kurokawa
J Clin Exp Hematop. 2023 Sep; 63(3): 187–192. Published online 2023 Aug 28. doi: 10.3960/jslrt.23023
PMCID:
PMC10628828
AbstractArticlePDF–1015K
12.
An Ultrafast UPLC–MS/MS Method for Characterizing the In Vitro Metabolic Stability of Acalabrutinib
Mohamed W. Attwa, Ahmed H. Bakheit, Ali S. Abdelhameed, Adnan A. Kadi
Molecules. 2023 Oct; 28(20): 7220. Published online 2023 Oct 23. doi: 10.3390/molecules28207220
PMCID:
PMC10609012
AbstractArticlePDF–3.5M
13.
CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy
Anfal Alsadhan, Jonathan Chen, Erika M. Gaglione, Chingiz Underbayev, Pamela L. Tuma, Xin Tian, Lita A. Freeman, Sivasubramanian Baskar, Pia Nierman, Susan Soto, Andy Itsara, Inhye E. Ahn, Clare Sun, Elena Bibikova, Tanja Nicole Hartmann, Maissa Mhibik, Adrian Wiestner
Clin Cancer Res. Author manuscript; available in PMC 2024 Mar 15.
Published in final edited form as: Clin Cancer Res. 2023 Sep 15; 29(18): 3612–3621. doi: 10.1158/1078-0432.CCR-22-3217
PMCID:
PMC10524232
AbstractArticlePDF–1.5M
14.
BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5
Derek B. Oien, Samanta Sharma, Maureen M. Hattersley, Michelle DuPont, Steven W. Criscione, Laura Prickett, Anne U. Goeppert, Lisa Drew, Yi Yao, Jingwen Zhang, Ho Man Chan
Blood Adv. 2023 Sep 12; 7(17): 5108–5121. Published online 2023 May 18. doi: 10.1182/bloodadvances.2022009257
PMCID:
PMC10477446
AbstractArticlePDF–2.4M
15.
Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Mark Roschewski, Manish R. Patel, Patrick M. Reagan, Nakhle S. Saba, Graham P. Collins, Hendrik-Tobias Arkenau, Sven de Vos, Barrett Nuttall, Melih Acar, Kathleen Burke, Rafael D. White, Maria Udriste, Shringi Sharma, Brian Dougherty, Daniel Stetson, David Jenkins, Andrew Mortlock, Alessandra Forcina, Veerendra Munugalavadla, Ian Flinn
Clin Cancer Res. 2023 Sep 1; 29(17): 3301–3312. Published online 2023 Jun 26. doi: 10.1158/1078-0432.CCR-22-2483
PMCID:
PMC10472096
AbstractArticlePDF–3.0M
16.
Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib
David Y. Lin, Amy H. Andreotti
PLoS One. 2023; 18(8): e0290872. Published online 2023 Aug 31. doi: 10.1371/journal.pone.0290872
PMCID:
PMC10470882
AbstractArticlePDF–1.5M
17.
A phase II study of Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis
Ragha V. Suresh, Collin Dunnam, Dhananjay Vaidya, Robert A. Wood, Bruce S. Bochner, Donald W. MacGlashan, Jr., Melanie C. Dispenza
J Clin Invest. 2023 Aug 15; 133(16): e172335. Published online 2023 Aug 15. doi: 10.1172/JCI172335
PMCID:
PMC10425211
AbstractArticlePDF–526K
18.
Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
Lindsey E. Roeker, Maral DerSarkissian, Kellie Ryan, Yan Chen, Mei Sheng Duh, Svea K. Wahlstrom, Shweta Hakre, Louise Yu, Helen Guo, Anthony R. Mato
Blood Adv. 2023 Aug 22; 7(16): 4291–4301. Published online 2023 May 12. doi: 10.1182/bloodadvances.2023009739
PMCID:
PMC10424141
AbstractArticlePDF–552K
19.
Ventricular arrhythmias and sudden death events following acalabrutinib initiation
Seema A. Bhat, John Gambril, Leylah Azali, Sunnia T. Chen, Lindsay Rosen, Marilly Palettas, Tracy E. Wiczer, Sujay Kalathoor, Qiuhong Zhao, Kerry A. Rogers, Adam Kittai, Michael Grever, Farrukh Awan, Patrick Ruz, John C. Byrd, Jennifer Woyach, Daniel Addison
Blood. 2022 Nov 17; 140(20): 2142–2145. Published online 2022 Aug 3. doi: 10.1182/blood.2022016953
PMCID:
PMC10405526
AbstractArticle
20.
Exploring the role of chemical reactions in the selectivity of tyrosine kinase inhibitors
Mojgan Asadi, Wen Jun Xie, Arieh Warshel
J Am Chem Soc. Author manuscript; available in PMC 2023 Jul 30.
Published in final edited form as: J Am Chem Soc. 2022 Sep 14; 144(36): 16638–16646. Published online 2022 Aug 31. doi: 10.1021/jacs.2c07307
PMCID:
PMC10387326
AbstractArticlePDF–1.0M

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > PubMed Central (PMC)
Support Center